Circular RNAs (circRNAs) have recently emerged as critical players in cancer biology, serving not merely as byproducts of splicing but as active regulators of gene expression. Their unique closed-loop structure endows them with remarkable stability, allowing them to act as molecular sponges that sequester microRNAs (miRNAs), thus indirectly influencing protein translation. This latest research focuses on one such circRNA, circ_001024—previously obscure yet now found to be highly overexpressed in RCC tumors.

Delving deep into circ_001024’s architecture, researchers employed Sanger sequencing complemented by RNase R digestion assays to validate its circular nature. Actinomycin D treatment further confirmed its resilience and prolonged half-life compared to linear counterparts. The robust presence of circ_001024 within RCC cells, primarily localized in the cytoplasm as revealed by Fluorescence in situ Hybridization (FISH), hints at its functional engagement in post-transcriptional gene regulatory mechanisms.

A series of quantitative real-time PCR experiments demonstrated significantly elevated levels of circ_001024 in tumor samples relative to adjacent normal tissue. Functional assays revealed that enforcing circ_001024 expression stimulated RCC cell proliferation, migration, and invasion—hallmarks of cancer aggressiveness. Conversely, targeted knockdown attenuated these malignant properties, suggesting a causative role of circ_001024 in facilitating tumor progression.

The mechanistic underpinnings became clearer with bioinformatics analyses pinpointing miR-145-3p as a potential interacting miRNA. Confirmatory dual-luciferase reporter assays elucidated a reciprocal binding relationship: circ_001024 acts as a miRNA “sponge,” competitively inhibiting miR-145-3p. This microRNA, known for tumor-suppressive functions, typically represses a set of oncogenic targets, including the GLUT5 protein—a key facilitator in cellular fructose uptake.

Subsequent RNA pull-down assays and rescue experiments cemented the axis of circ_001024, miR-145-3p, and GLUT5 in RCC pathophysiology. Overexpressing miR-145-3p partially reversed the oncogenic effects driven by circ_001024, corroborating that circ_001024’s malignant influence is mediated through miR-145-3p sequestration. Western blot analyses further revealed GLUT5 protein levels mirroring circ_001024 expression, linking enhanced fructose metabolism to RCC advancement.

Intriguingly, clinicopathological correlation studies depicted GLUT5 expression as significantly associated with the WHO/ISUP grading of RCC tumors—a critical determinant of malignancy and prognosis. This association, however, did not extend to patient age, gender, tumor size, or TNM staging, underscoring GLUT5’s potential role as a biomarker for tumor aggressiveness rather than tumor burden.

These revelations underscore a novel metabolic regulatory mechanism in RCC, where circ_001024 modulates the metabolic landscape through GLUT5 by titrating miR-145-3p availability. The study situates metabolic adaptation at the nexus of RCC progression, highlighting fructose metabolism as a previously underappreciated contributor to renal carcinogenesis.

Beyond the molecular implications, the translational potential of these findings is vast. Therapeutically targeting circ_001024—either by disrupting its miRNA-binding capacity or by enhancing miR-145-3p function—could impair GLUT5-mediated metabolic pathways, potentially starving RCC cells of vital nutrients required for rapid growth and invasiveness.

Moreover, the study’s advanced methodological framework combines transcriptomic validations, functional perturbations, and clinical data integration—establishing a robust template for future circRNA investigations in cancer biology. These comprehensive approaches ensure that the observed effects are not artifacts but reflect genuine biological processes relevant to tumor progression.

As RCC remains notoriously resistant to conventional therapies, the identification of circ_001024 and its interactive network with miR-145-3p and GLUT5 offers fresh hope. It invites a paradigm shift towards targeting RNA-based regulatory circuits and metabolic dependencies in cancer, a strategy that may eventually translate into personalized and more effective treatment modalities.

In conclusion, this pioneering work unravels the sophisticated endogenous competition between circRNAs and miRNAs in RCC, highlighting circ_001024’s role as a molecular decoy that subverts miR-145-3p suppression of GLUT5. This intricate regulatory mechanism not only advances our understanding of RCC pathogenesis but also charts a promising course for future research and therapeutic innovation.

Subject of Research:
The regulatory role of circ_001024 in renal cell carcinoma progression via competitive binding to miR-145-3p and consequent modulation of GLUT5.

Article Title:
Role and mechanism of circ_001024 endogenous competition for miR-145-3p targeting to regulate GLUT5 in RCC

Article References:
Zhao, L., Xu, J., Li, D. et al. Role and mechanism of circ_001024 endogenous competition for miR-145-3p targeting to regulate GLUT5 in RCC. BMC Cancer 25, 1713 (2025). https://doi.org/10.1186/s12885-025-14878-3

Image Credits: Scienmag.com

DOI:
05 November 2025

Keywords:
Renal cell carcinoma, circular RNA, circ_001024, miR-145-3p, GLUT5, fructose metabolism, tumor progression, RNA sponging, molecular oncology

Renal cell carcinoma is the predominant malignancy affecting the kidneys, representing approximately 85% of adult renal cancers. Its notoriously poor prognosis and limited treatment options have propelled research efforts toward understanding the molecular underpinnings of RCC progression and therapy resistance. Ferroptosis is now recognized as a promising pathway for cancer suppression, and previous studies have implicated acyl-CoA synthetase long-chain family member 4 (ACSL4) as a pivotal executor of this cell death modality. ACSL4 catalyzes the esterification of polyunsaturated fatty acids into membrane phospholipids, thereby sensitizing cells to ferroptotic induction via lipid peroxidation. However, the molecular mechanisms that regulate ACSL4’s stability and function in RCC have yet to be fully defined.

Protein arginine methyltransferase 5 (PRMT5) is a member of the PRMT family that catalyzes the symmetrical dimethylation of arginine residues on target substrates. PRMT5 has been increasingly recognized as an oncogenic driver implicated in numerous cancers, including RCC, through epigenetic and post-translational modifications. These modifications modulate protein function, gene expression, RNA processing, and signal transduction acting as critical regulators of tumor cell biology. Dr. Zhang’s research team hypothesized that PRMT5 exerts control over ferroptosis in renal cancer cells by modulating ACSL4 through arginine methylation, thus influencing RCC proliferation and survival via ferroptosis resistance mechanisms.

The study employed a comprehensive experimental approach utilizing RCC cell lines, patient-derived tumor samples, and in vivo animal models to dissect the functional relationship between PRMT5 and ACSL4 in ferroptosis regulation. An extensive screening of approximately 765 epigenetic compounds was conducted to identify novel modulators influencing ferroptosis in renal cancer cells. Subsequent molecular assays included cell viability analyses, protein expression profiling, methylation detection techniques, and ferroptosis-specific markers monitoring. The combinatorial methodologies allowed the researchers to delineate how PRMT5-dependent methylation at arginine 549 destabilizes ACSL4, thereby attenuating its pro-ferroptotic activity.

Mechanistically, the researchers revealed that PRMT5 symmetrically dimethylates the arginine residue located at position 549 on ACSL4 (meR549-ACSL4). This post-translational modification flags ACSL4 for proteasomal degradation through its enhanced binding affinity with UBR5, an E3 ubiquitin ligase central to protein turnover regulation. The diminished ACSL4 protein stability translates into decreased lipid incorporation of polyunsaturated fatty acids, subsequently suppressing lipid peroxidation and ferroptotic processes. As a result, RCC cells acquire ferroptosis resistance, which promotes tumor cell survival and potential expansion.

The implications of this regulatory axis were further corroborated by experiments involving PRMT5 inhibition. When PRMT5 expression was pharmacologically or genetically suppressed, a significant restoration of ACSL4 stability was observed, alongside marked increases in ferroptosis induction in renal cancer cells. This reversal of ferroptosis resistance not only reduced tumor cell viability but also sensitized RCC cells to immunotherapeutic treatments such as programmed death-1 (PD-1) blockade. The synergy between ferroptosis enhancement and immunotherapy opens new therapeutic vistas for refractory RCC.

Among the exciting therapeutic insights, the study identified GSK3326595, a specific and potent PRMT5 inhibitor, as a promising candidate to harness ferroptosis-mediated antitumor effects. The integration of GSK3326595 with PD-1 immune checkpoint inhibitors demonstrated marked tumor suppression in preclinical models. This combinatorial approach leverages the dual benefits of directly triggering ferroptotic cell death and invigorating antitumor immunity, a strategy with the potential to surmount therapy resistance barriers prevailing in RCC treatments.

The newfound role of PRMT5 as a modulator of ferroptosis also raises broader questions about epigenetic and post-translational modifications in cancer biology. Targeting arginine methylation provides a novel dimension for therapeutic intervention that extends beyond gene expression to the dynamic modulation of protein stability and function. This research underpins an increasingly appreciated intersection between epigenetic regulatory enzymes and cell death pathways, presenting fertile ground for future drug development initiatives.

Importantly, this investigation employed patient-derived data and animal models to confirm the clinical relevance of the PRMT5-ACSL4-ferroptosis axis in RCC prognosis. Elevated PRMT5 expression correlated with poorer patient outcomes, consistent with its role in promoting ferroptosis resistance and tumorigenic potential. These translational findings propel this research beyond basic science into the realm of clinical oncology, laying the foundation for future trials aimed at evaluating the safety and efficacy of PRMT5 inhibitors as adjuncts to existing kidney cancer therapies.

Ferroptosis, originally conceptualized less than a decade ago, is increasingly recognized as a fulcrum for novel cancer therapeutic strategies, particularly in malignancies that evade apoptosis. This study provides critical evidence positioning PRMT5-mediated arginine methylation of ACSL4 as a fundamental mechanism by which renal cancer cells subvert ferroptotic cell death. Furthermore, it elucidates a promising pharmacologic target—PRMT5 inhibition—to overcome ferroptosis resistance and enhance immunotherapy efficacy in RCC.

Given the complexity of ferroptosis regulation and tumor immunology, further in-depth mechanistic studies and clinical evaluations are necessary to validate and optimize the therapeutic strategies proposed. Nevertheless, the findings reported by Dr. Zhang’s team constitute a paradigm shift that integrates epigenetic modulation with ferroptosis-based interventions, potentially heralding a new era in cancer treatment focusing on overcoming resistance through combined metabolic and immune-targeted therapies.

In conclusion, the elucidation of PRMT5’s methylation of ACSL4 at arginine 549 as a critical suppressor of ferroptosis resistance not only advances our molecular understanding of RCC biology but offers an actionable target for innovative treatment modalities. The prospect of combining PRMT5 inhibitors with immune checkpoint blockade therapies represents a promising development in precision oncology, poised to improve outcomes for RCC patients who currently face limited therapeutic options.

Subject of Research: Cells

Article Title: PRMT5-Mediated Arginine Methylation of ACSL4 Attenuates Its Stability and Suppresses Ferroptosis in Renal Cancer

News Publication Date: 1-Aug-2025

Web References: http://dx.doi.org/10.34133/research.0789

Image Credits: Wellcome Collection via the Creative Commons Search Repository

Keywords: Ferroptosis, Renal Cell Carcinoma, PRMT5, ACSL4, Arginine Methylation, Lipid Peroxidation, Protein Stability, Immunotherapy, Tumor Suppression, Epigenetic Regulation, GSK3326595, PD-1 Blockade